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Familial hypertrophic cardiomyopathy (HCM) is a primary myocardial disease with a prevalence of 1 in 500 in human beings. Causative
mutations have been identified in several sarcomeric genes, including the cardiac myosin binding protein C (MYBPC3) gene. Heritable HCM also
exists in a large-animal model, the cat, and we have previously reported a mutation in the MYBPC3 gene in the Maine coon breed. We now report
a separate mutation in the MYBPC3 gene in ragdoll cats with HCM. The mutation changes a conserved arginine to tryptophan and appears to alter
the protein structure. The ragdoll is not related to the Maine coon and the mutation identified is in a domain different from that of the previously
identified feline mutation. The identification of two separate mutations within this gene in unrelated breeds suggests that these mutations occurred
independently rather than being passed on from a common founder.
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disease characterized by increased left ventricular mass and
wall thickness in the absence of a pressure overload or
metabolic stimulus [1]. In human beings, it has a disease
prevalence of 1 in 500 and is inherited, usually as an autosomal
dominant trait, in at least 60% of the cases [1]. Causative
mutations are most commonly single base pair substitutions
found in one of several sarcomeric genes (β myosin heavy
chain; cardiac myosin binding protein C; cardiac troponins T, I,
and C; α tropomyosin; the essential and regulatory light chains;
actin; and titin) [2–8].
Hypertrophic cardiomyopathy is the most common form of
heart disease in the cat [9]. Affected cats are at risk of sudden
cardiac death, development of congestive heart failure, and
development of a systemic arterial thromboembolus. Increas-
ingly, feline hypertrophic cardiomyopathy is noted to be present
in specific breeds, with examples reported in the Maine coon,
ragdoll, and British shorthair breeds, among others [9]. We have⁎ Corresponding author. Fax: +1 509 335 0880.
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doi:10.1016/j.ygeno.2007.04.007recently identified a causative mutation for inherited hyper-
trophic cardiomyopathy in the Maine coon cat in the gene for
the cardiac myosin binding protein C (MYBPC3), a sarcomeric
gene and the second most common cause of familial
hypertrophic cardiomyopathy in human beings [3,8,10,11].
The Ragdoll cat has also been reported to have a breed-specific
form of hypertrophic cardiomyopathy. Some studies suggest a
unique early onset form of the disease, with affected cats having
an average age of diagnosis of 15 months compared to the
reported age of diagnosis of 5–7 years for the general feline
hypertrophic cardiomyopathy population [9,12].
The ragdoll breed is thought to be distantly related to the
Persian cat breed and is not known to be related to the Maine
coon cat breed [13]; therefore, it is unlikely to have a shared
mutation passed down from a single founder. We hypothesized
that this breed would have a unique mutation for hypertrophic
cardiomyopathy, consistent with the allelic heterogeneity
observed in human beings. The objective of this study was to
evaluate the exonic and splice site regions of the cardiac myosin
binding protein C gene in ragdoll cats with hypertrophic
cardiomyopathy by PCR-based sequencing.
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DNA samples from 21 ragdoll cats (10 female, 11 male) with
a diagnosis of hypertrophic cardiomyopathy were submitted for
evaluation. Age of diagnosis ranged from 9 months to 5 years.
Eight of the cats were members of two families. In Family 1,
both parents and three available offspring were known to be
affected. In Family 2, both parents and one offspring were
affected.
DNA sequencing revealed a single base pair change from a C
to T in codon 820 in all of the affected cats (9 homozygotes, 11
heterozygotes) and none of the unaffected control cats. This
change in the first base pair of the codon altered a conserved
amino acid from arginine, a basic, positively charged amino
acid, to tryptophan, a neutral, aromatic, hydrophobic amino acid
(Table 1). No other mutations in other exonic or splice site
regions of theMYBPC3 gene were identified in affected ragdoll
cats. The previously reported Maine coon mutation in exon 3 of
MYBPC3 (A31P) was not identified in any of the affected
ragdoll cats [11].
The potential impact of this amino acid substitution was
evaluated with PolyPhen (http://tux.embl-heidelberg.de/
ramensky/polyphen.cgi). The substitution was predicted to be
“probably damaging,” with a PSIC score difference of 2.552,
which implies a high confidence that the substitution affects
protein function or structure. Protein structure analysis
programs predicted a disruption of the α-helix structure and
an increase in extended strand within the domain containing the
mutation. The GOR4 program predicted that in the region of
interest in the normal cat, 44% will be an α-helix structure, 9%
in an extended strand, and 47% in a random coil. Evaluation of
the same region containing the amino acid substitution
predicted that the region would be 40% α helix, 17% extended
strand, and 43% random coil. The Protean program also
predicted an increase in the hydrophobicity in this region of the
molecule in the affected cats (Fig. 1).
Age of diagnosis was available for all 9 of the cats
homozygous for the mutation and ranged from 4 to 48 months
(mean of 21 months). The age of diagnosis was available for 11
of the cats heterozygous for the mutation and ranged from 9 to
65 months (mean of 39 months). The age of diagnosis between
the heterozygous and the homozygous cats was not significantly
different.Table 1
Partial amino acid sequence of the MYBPC3 transcript across species
Human YILERKKKKSYRWMRLNFDLLRELSHEARRMIEGV
Mouse YILERKKKKSYRWMRLNFDLLRELSHEARRMIEGV
Rat YILERKKKKSYRWMRLNFDLLRELSHEARRMIEGV
Dog YILERKKKKSYRWMRLNFDLLRELSHEARRMIEGV
Cow YILERKKKKSYRWMRLNFDLLRELSHEARRMIEGV
Cat, normal YILERKKKKSFRWMRLNFDLLQELSHEARRMIEGV
Cat, mutation YILERKKKKSFRWMWLNFDLLQELSHEARRMIEGV
Partial amino acid sequence of the MYBPC3 transcript demonstrates the
conservation of the arginine amino acid (R820) across species (GenBank Accession
Nos. AY5183901, CAM17567L, XP_21577, DQ23807.1, BC119825.1). The
ragdoll cardiomyopathy mutation changes the first base pair of the codon, which
alters the amino acid to tryptophan (R820W).In this report, we have identified the second mutation known
to cause an inherited form of hypertrophic cardiomyopathy in
the domestic cat. This newly identified mutation in the ragdoll
cat was found in the myosin binding protein C gene, the same
gene as the previously reported mutation in the Maine coon cat
breed but in a different region of the gene [11]. In the Maine
coon cat the amino acid affected (A31P) was located in the
linker region between domains C0 and C1 of the protein. The
functional aspects of that area are not well understood, but there
is some evidence that domain C0 and the C0–C1 linker region
may bind to myosin and/or actin [14–17]. The mutation re-
ported in ragdoll cats is located in domain 6, a fibronectin type
III region. Causative mutations for the human form of the
disease have been observed within this domain as well,
including a 3-bp deletion that affects the same codon as the
one containing the mutation we describe [8,18–21]. A specific
function for domain 6 has not yet been identified, although it
has been suggested that it may interact with domain 9 to form
overlapping regions that provide a collar around the sarcomeric
myosin heavy chain thick filament [14,22]. This theory is
supported by a previous study proposing interactions of
domains 5 and 8, as well as 7 and 10 [22]. If this is the case,
the amino acid change from arginine, a simple basic amino acid,
to tryptophan, a very large aromatic amino acid, and the
subsequent proposed change in secondary structure may
interfere with these domain interactions.
Hypertrophic cardiomyopathy in the ragdoll cat has been
previously characterized as an early onset form of the feline
disease [12]. In one study, affected cats had an average age of
diagnosis of 15 months (range, 5–24 months) compared to the
reported age of onset of 4.8–7 years for the general feline
hypertrophic cardiomyopathy population [9,12]. Although the
study described here was not designed to evaluate closely for
genotypic to phenotypic correlations it may be of interest that
the cats that were homozygous for the mutation appeared to
develop the disease, on average, 18 months earlier than the
heterozygotes. This is consistent with our previous report of
the MYBPC3 mutation in Maine coon cats, for which the
clinical outcome of the disease also varied with genotype. In
that study, a larger number of cats homozygous for the
mutation developed moderate to severe disease and most died
of their disease at 4 years of age or less, whereas 3 of
10 Maine coon cats heterozygous for the mutation were still
alive at 8–12 years of age, with moderate disease [11]. Two
human studies have also suggested a role for gene dosage on
the phenotype of hypertrophic cardiomyopathy mutations,
including examples in the MYBPC3 gene [8,19]. In one study,
the same mutation at codon 810 was observed in two
unrelated human patients. One individual was homozygous
for the mutation and had severe left ventricular hypertrophy,
while the other individual was heterozygous for the mutation
and demonstrated only moderate nonobstructive hypertrophy
[19].
In this study, we describe the second mutation associated
with feline hypertrophic cardiomyopathy. Although this muta-
tion is in the same gene as the previously reported feline
mutation, its location is in a domain distant from the previously
Fig. 1. Secondary structure analysis predicted that the change from (a) arginine to (b) tryptophan would result in a disruption of the α-helix and β-sheet structure
and increased hydrophobicity (arrow denotes amino acid region, more hydrophobic above the line, less hydrophobic below the line) of the molecule in the mutated
region.
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ragdoll cat, the results reported here suggest that this mutation
developed independently in the ragdoll cat breed, as opposed to
a founder effect mutation brought in from a shared founder in
one breed. The identification of two separate feline MYBPC3
hypertrophic cardiomyopathy mutations in these two different
breeds is consistent with the allelic heterogeneity observed in
the human disease [8].
Numerous examples of both allelic and genetic heterogeneity
have been identified within sarcomeric genes in human beings
with HCM [2–8]. The results of this feline study demonstrate
that allelic heterogeneity also exists in the cat with hypertrophic
cardiomyopathy. Additional studies to evaluate the develop-
ment of mutations within this gene as well as the effect of this
specific mutation on the c-MyBP-C protein interactions and
function are needed.
Materials and methods
DNA samples were obtained from 21 affected ragdoll cats previously
diagnosed with hypertrophic cardiomyopathy by identification of left ventricular
wall thicknesses exceeding the normal feline values and, sometimes, papillary
muscle hypertrophy, as determined by echocardiography [9]. DNA samples
were also obtained from 110 unaffected cats (controls) from a variety of different
breeds, including ragdolls (19), sphinx (6), Maine coon (12), domestic shorthair
(10), pixie bob (4), Bengal (4), Scottish fold (7), Persian (2), and rex (4), as well
as mixed-breed cats (42).
The sequences of the exonic and splice site regions of the feline MYBPC3
gene were extracted from feline contigs using the Blast function of NCBI and thehuman sequence (GenBank Accession No. U91629). Amplification primers
were designed for each of the 35 exons using Primer 3 software [23].
Standard PCR amplifications were carried out using NH4SO4 buffer,
0.1 unit/μl reaction volume Taq DNA polymerase (Fermentas, Hanover, MD,
USA), 2.5 mM MgCl2, 12.5 μM each dNTP, 2.5 mM each PCR amplification
primer, and approximately 100 ng of template DNA. Samples were denatured
for 5 min at 94°C followed by 40 cycles of 94°C for 30 s, 58°C for 30 s, 72°C for
30 s, and finally 72°C for 7 min. The annealing temperature was optimized to
accommodate the respective primer.
Residual amplification primers and dNTPs were removed from the PCR
product using a gel extraction kit (Millipore, Bedford, MA, USA). Amplicons
were then subjected to nucleotide sequence determination and analyzed on an
ABI Prism 377 sequencer (Applied Biosystems, Foster City, CA, USA).
The nucleotide sequences were initially evaluated for a sequence change
between affected cats, the published normal feline sequence, and two control
mixed-breed cats. A base pair change was to be considered causative for
hypertrophic cardiomyopathy if it met the following criteria: was present in the
affected cats but not the controls or the published feline sequence, changed a
conserved amino acid, or changed the amino acid to one of a different polarity,
acid/base status, or structure. The change that met the above criteria was then
evaluated in 108 additional control cats.
Subsequently the amino acid substitution identified was evaluated with the
PolyPhen (http://tux.embl-heidelberg.de/ramensky/polyphen.cgi) program to
predict the possible impact of the amino acid substitution on the protein.
PolyPhen was used to predict the likelihood that the substitution was
damaging and to calculate PSIC scores, which represent the logarithmic ratio
of the likelihood of a given amino acid occurring at a particular site relative to
the likelihood of this amino acid occurring at any site [24]. A PSIC score
difference above 2 indicates a damaging effect, between 1.5 and 2 suggests
that the variant is possibly damaging, and below 0.5 indicates that the variant
is benign.
Finally, the normal and altered sequences were evaluated for changes that
might occur in the secondary structure with two protein structure software
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GOR4 predicts the probability of a secondary structure at each amino acid
position. Protean used the Eisenberg method to predict the hydrophobicity of the
region based on computation and experimental measurements that describe the
distribution of hydrophilic and hydrophobic residue groups in a protein.
A t test was performed to determine if there was a significant difference in
the age of diagnosis between the heterozygous and the homozygous cats. A
value of pb0.05 was considered significant.
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